Bausch + Lomb buys US rights to Stada’s Lucentis biosimilarBausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches Share XBausch + Lomb buys US rights to Stada’s Lucentis biosimilarhttps://pharmaphorum.com/news/bausch-lomb-buys-us-rights-to-stadas-lucentis-biosimilar/
